Cargando…

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases

SIMPLE SUMMARY: Leptomeningeal disease in melanoma (LMM) patients is characterized by aggressiveness and dismal outcomes. Clinical studies and case reports demonstrate the potential of immune and targeted therapies (especially in combinatorial or multi-modal settings) in improving survival for some...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khaled, Mariam Lotfy, Tarhini, Ahmad A., Forsyth, Peter A., Smalley, Inna, Piña, Yolanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047692/ https://www.ncbi.nlm.nih.gov/pubmed/36980770 http://dx.doi.org/10.3390/cancers15061884

Ejemplares similares

Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review
por: Wallace, Gerald, et al.
Publicado: (2023)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
por: Ferguson, Sherise D., et al.
Publicado: (2022)

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)

SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING
por: Pina, Yolanda, et al.
Publicado: (2023)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival
por: Smalley, Inna, et al.
Publicado: (2021)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)

BSCI-01 INTRATHECAL DELIVERY OF DENDRITIC CELL VACCINE ERADICATES TUMOR GROWTH AND PROTECTS AGAINST LEPTOMENINGEAL DISEASE (LMD) RE-INOCULATION IN IMMUNOCOMPETENT HER2+ AND TRIPLE NEGATIVE BREAST CANCER (TNBC) LMD XENOGRAFT MODELS
por: Law, Vincent, et al.
Publicado: (2022)

LMD-04. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2021)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma
por: Law, Vincent, et al.
Publicado: (2022)

LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021)

LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease
por: Najem, Hinda, et al.
Publicado: (2021)

LPTO-03. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES
por: Law, Vincent, et al.
Publicado: (2019)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM)
por: Fitzpatrick, Amanda, et al.
Publicado: (2021)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Brenner, Andrew, et al.
Publicado: (2021)

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
por: Law, Vincent, et al.
Publicado: (2021)

Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment
por: Steininger, Julian, et al.
Publicado: (2023)

Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
por: Tétu, Pauline, et al.
Publicado: (2020)

How we treat patients with leptomeningeal metastases
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Leptomeningeal Metastases: New Opportunities in the Modern Era
por: Wilcox, Jessica A., et al.
Publicado: (2022)

Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer
por: Morganti, Stefania, et al.
Publicado: (2023)

Leptomeningeal Disease and Hydrocephalus as the First Presentation of Melanoma
por: Sawalha, Ahmad, et al.
Publicado: (2023)

Metastatic Melanoma With Leptomeningeal Disease
por: Marinova, Amanda M., et al.
Publicado: (2021)

TIPS-04 A RANDOMIZED, MULTI-INSTITUTIONAL PILOT STUDY TO EVALUATE THE MOLECULAR AND CELLULAR RESPONSE TO TREATMENT WITH NIVOLUMAB WITH EITHER ADJUVANT IPILIMUMAB OR RELATLIMAB IN ADULT PATIENTS WITH SURGICALLY RESECTABLE MELANOMA BRAIN METASTASES: ONGOING TRIAL
por: Pina, Yolanda, et al.
Publicado: (2023)

Ovarian Adenocarcinoma With Leptomeningeal Metastases
por: Bayas, Angel, et al.
Publicado: (2022)

Helical tomotherapy in patients with leptomeningeal metastases
por: Schiopu, Sanziana RI, et al.
Publicado: (2018)

Leptomeningeal disease in neurosurgical brain metastases patients: A systematic review and meta-analysis
por: Tewarie, Ishaan Ashwini, et al.
Publicado: (2021)

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
por: Wilcox, Jessica A., et al.
Publicado: (2022)

Management of Brain and Leptomeningeal Metastases from Breast Cancer
por: Pellerino, Alessia, et al.
Publicado: (2020)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers
por: Dankner, Matthew, et al.
Publicado: (2021)

Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making
por: Lamba, Nayan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bk18glvlh6obv84ul2d1jg03ao